The high cost of living is a reality many grapple with, and biotechs are no exception. Medigene and Idorsia are active in very different therapeutic areas but have butted up against similar difficulties, and both are attempting to cope by shedding staff.
Idorsia And Medigene Cut Jobs To Keep Going
Both companies are seeking to license their products as they try to stretch their dwindling cash.
More from Business
• By
The latest in a long line of restructuring moves will see Sumitomo Pharma selling its pharma operations in Asia to major Japanese trading house Marubeni.
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
More from Therapy Areas
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus